We report clinical outcomes following transcatheter aortic valve implantation (TAVI), using the CoreValve revalving system (18 Fr transfemoral or subclavian) or the Edwards Sapien valve (22 Fr transfemoral or 24 Fr transapical) as part of a Belgian prospective nonrandomized multicentre registry. All 15 Belgian centres performing TAVI participated to this registry (seven exclusively Edwards Sapien, eight exclusively CoreValve). All consecutive high-risk symptomatic patients with severe aortic stenosis were evaluated by a heart team and screened for eligibility for TAVI. Three hundred and twenty-eight patients underwent TAVI with CoreValve (ns141; eight subclavian and 133 transfemoral) or Edwards Sapien (ns187; 99 transfemoral and 88 transapical) up to April 2010. Procedural success was 97%. Onemonth survival was 88% for the Edwards and 89% for the CoreValve treated patients. One-month mortality was both related to cardiac and non-cardiac reasons. Overall one-year survival was 78% in the CoreValve transfemoral treated patients, 100% in the CoreValve subclavian treated patients, 82% in the Edwards transfemoral treated patients and 63% in the Edwards transapical treated patients. This mid-term mortality was mainly related to age-related, non-cardiac complications.
Introduction
Surgical aortic valve replacement (SAVR) is the primary treatment modality recommended for severe aortic stenosis, offering both symptomatic and prognostic benefits. However, the need for a less-invasive, non-surgical treatment option for high-risk patients has recently culminated in development of transcatheter aortic valve implantation (TAVI). Currently, two devices are clinically in use. The Edwards Sapien valve is a bovine pericardium prosthesis mounted on a balloon-expandable stent that is placed in the subcoronary position. It can be placed by an antegrade (transapical) or retrograde (transfemoral) approach. The CoreValve transcatheter aortic valve is a self-expanding nitinol frame porcine pericardium prosthesis, placed by a retrograde (transfemoral or subclavian) approach.
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Randomized trials that are currently underway will confirm procedural safety and guide the applicability of this technology. In the mean time, carefully performed national registries monitoring all TAVI outcome data of both devices can already be of value in defining the potential clinical role of this new technology in high-risk symptomatic patients refused for SAVR w1-4x. The Belgian TAVI Registry is a prospective, non-randomized multicenter national registry, aiming to include and follow-up all consecutive Belgian TAVI procedures.
Methods

The Belgian TAVI Registry
All 15 Belgian cardiac centres, performing TAVI, participated to this Belgian TAVI Registry. In seven of these centres, the Edwards Sapien valve was exclusively used and in eight of these, the CoreValve device was exclusively used. All consecutive TAVI procedures were included. Patient follow-up was obtained during and immediately after valve implantation, and at 1, 6 and 12 months. Collection of patient data for the Belgian TAVI Registry was approved by the institutional Ethics Committee of the different participating centres.
Events and values collected are site recorded, and there are no core laboratories. Data pooling and statistical analysis was performed at the University of Antwerp.
Patients
TAVI was considered by the heart team in symptomatic patients with significant aortic valve stenosis who were not good candidates for surgical aortic valve replacement.
Statistical analysis
Continuous variables are presented as means ("S.D.) and were compared with the use of Student's t-test. In case of non-normal distribution, Mann-Whitney test was used. Categorical variables were compared with the use of Fisher's exact test. Survival curves for time-to-event variables were constructed on the basis of all available follow-up data with the use of Kaplan-Meier estimates and were compared with the use of the log-rank test.
Results
Patient population
Three hundred and twenty-eight consecutive patients who underwent TAVI until April 2010 were enrolled in this registry. Of the 187 Edwards treated patients, 53% (ns99) was treated transfemoral and 47% (ns88) by transapical approach. Of the 141 CoreValve treated patients, 94% (ns133) was treated transfemoral, and 6% (ns8) by subclavian approach. Baseline characteristics of the patients are reported in Table 1 .
Procedural results and one-month clinical events and survival
Procedural success (Table 2) was very high in both treatment groups wEdwards (97%); CoreValve (98%); non-significant (NS)x. Procedural mortality was 3% in the Edwards treated patients and 2% in the CoreValve treated patients (non-significant, NS). Reasons of procedural mortality are summarized in Table 3 . One month outcome data are summarized in Table 4 . The need for a new definitive pacemaker implantation was significantly higher in the CoreValve treated patients compared to the Edwards treated patients. The incidence of renal failure (meaning dialysis needed), clinical stroke or transient ischemic attack (TIA) within the first month after TAVI was comparable between both treatment groups.
One-month survival was 88% for the Edwards and 89% for the CoreValve treated patients (NS). Causes of mortality are summarized in Table 5 and almost equally distributed between cardiac and non-cardiac reasons.
One-year clinical events and survival
One year clinical outcome data are summarized in Fig. 1 . Overall one-year survival was 78% in the CoreValve transfemoral treated patients, 100% in the CoreValve subclavian treated patients, 82% in the Edwards transfemoral treated patients and 63% in the Edwards transapical treated patients. Causes of mortality within the first year are summarized in Table 5 and mainly related to non-cardiac reasons.
Edwards Sapien transfemoral vs. transapical treated patients: patient characteristics and long-term outcome
Data are summarized in Table 6 and Fig. 1 . One-year survival of the transapically treated Edwards Sapien patients was significantly less compared to the transfemorally treated patients.
One-year echographic follow-up
Data are summarized in Fig. 2 and based on complete one-year echographic follow-up in 117 patients (60 CoreValve and 57 Edwards Sapien). Post-procedural transaortic pressure gradients were markedly low in both groups. During the first year after TAVI, no significant deterioration of the gradients was documented. No prosthetic structural deterioration or non-structural dysfunction was observed.
Discussion
Waiting final conclusions of randomized trials, carefully performed national registries, monitoring acute and longterm safety and efficacy results, both of CoreValve (transfemoral, subclavian) and Edwards (transfemoral, transapical) TAVI treated patients are of importance in Fig. 1 . Kaplan-Meier survival curves, expressing one-year survival after TAVI. TAVI, transcatheter aortic valve implantation; TF, transfemoral; TA, transapical; SC, subcalvian. 
LVEF, left ventricular ejection fraction; PVD, peripheral arterial disease; ao, aorta; prev CABG, previous coronary artery bypass grafts; carotid dis, carotid disease.
understanding better possible clinical value of this new treatment modality for high-risk patients.
The Belgian TAVI Registry
The Belgian TAVI Registry is a carefully conducted prospective, non-randomized multicenter national registry, aiming to include and follow-up all Belgian TAVI procedures. In contrast to some other national or single centre registries, all consecutive TAVI patients in Belgium, both treated by the Edwards Sapien valve or by the CoreValve prosthesis, are included in this registry. Moreover, mid-term follow-up was completed in a very high number of patients. If possible, the reason of death was documented. Although there is no formal central core laboratory, both the Belgian Working Group for Interventional Cardiology and the Belgian Working Group for Cardiac Surgery stimulated participating sites for providing high-quality patient data.
Procedural results and one-month clinical events and survival
After careful selection of patients with severe symptomatic aortic valve stenosis, refused for surgery and with acceptable additional technical evaluation, TAVI can be successfully performed in a high number of patients, with low procedural mortality. This finding is confirmed by many other similar registries w1-4x. The main reasons for procedural mortality are related to suboptimal guidewire manipulation wleading to left ventricle (LV) perforationx, suboptimal aortic root measurements (leading to severe aortic valve regurgitation or annulus rupture) or major vascular complications (bleeding or dissection).
One-month mortality after TAVI is almost equally distributed between cardiac and non-cardiac causes. Three patients died due to suboptimal manipulation of the temporary pacing electrode with severe tamponade and collapse, while at least four others died due to too rapid removal or dislocation of the pacing electrode with occurrence of conduction disturbances and arrest. This finding focuses our attention to the need of improved post-procedural care and better and more uniform guidelines to pacemaker management after TAVI. Another two to five patients died within the first weeks after TAVI due to severe aortic valve regurgitation related to valveyannulus mismatch or valve undersizing. This finding focuses on even more careful technical selection (evaluation of aortic root dimensions) of potential TAVI patients. Finally, 13 patients died due to non-cardiac complications of which some (pneumonia, sepsis, «) are probably related to too high frailty of selected patients.
Mid-term outcome after TAVI
One-year survival in this high-risk population is good, mainly in the transfemorally and subclavian (only limited group) CoreValve treated patients and the transfemorally treated Edwards Sapien patients. Survival rates are probably significantly more, than what was predicted by different risk scores in this patient population. Our registry demonstrates that causes of mid-term mortality are mainly (20y 28) related to age-dependent complications and are probably not related to, or cannot be prevented by TAVI. Long-term cardiac mortality seems to be relatively low after TAVI, in a patient population which was initially strongly symptomatic with high chance of cardiac death.
Although non-randomized registries are not designed to compare different treatment strategies, a remarkable observation in our registry is the significantly higher midterm mortality of the transapically treated Edwards Sapien patients, compared to the transfemorally treated Edwards Sapien patients and the CoreValve treated patients. Whether this is related to different baseline patient characteristics or to other procedural elements, cannot be answered by our data.
Limitations
There were no centres performing both CoreValve and Edwards procedures. The number of patients is relatively limited, comparison of treatment strategies (Edwards Sapien vs. CoreValve) (transfemoral vs. transapical) is not mandatory in a non-randomized registry and there is no central core laboratory monitoring all events.
Conclusions
Percutaneous aortic valve replacement for selected patients with severe aortic valve stenosis is associated with a low acute and mid-term mortality in a high-risk population. Further progress in better technical patient selection, careful post-procedural care and evaluation of most optimal access are essential to improve actual results.
